Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Hyperhydration is not necessary for high-dose melphalan in stem cell transplantation

Bone Marrow Transplantation volume 55, pages 827–829 (2020)Cite this article

Subjects

To the Editor,

High-dose melphalan (120–200 mg/m2) is widely used in preparative regimens for autologous and allogeneic haematopoietic stem cell transplantation (HSCT).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Product Information. ALKERAN® ApoPharm USA Inc, 2011.

  2. High Dose Melphalan Guideline. South West Clinical Network NHS, 2017. http://www.swscn.org.uk/wp/wp-content/uploads/2014/12/High-dose-melphlan.pdf. Accessed March 2019.

  3. Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, et al. High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. Bone Marrow Transplant. 2015;50:499–504.

    Article  CAS  Google Scholar 

  4. McElwain TJ, Hedley DW, Burton G, Clink HM, Gordon MY, Jarman M, et al. Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high dose melphalan. Br J Cancer. 1979;40:72–80.

    Article  CAS  Google Scholar 

  5. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet. 1983;322:822–4.

    Article  Google Scholar 

  6. Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Cancer Chemother Pharm. 1986;16:300–5.

    Article  CAS  Google Scholar 

  7. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GEG, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood. 2003;101:2144–51.

  8. eviQ. Guidelines. www.eviq.org.au

  9. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney International Supplements. 2012;2:1.

Download references

Acknowledgements

We wish to acknowledge ESA International and the Leukaemia Foundation for their financial support for the presentation of this study at the European Society for Blood and Marrow Transplantation Meeting 2018.

Author information

Authors and Affiliations

  1. Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, QLD, 4029, Australia

    Midori Nakagaki, Elise Button, Amy Keating & Glen A. Kennedy

  2. School of Nursing, Queensland University of Technology, Victoria Park Road, Kelvin Grove, QLD, 4059, Australia

    Elise Button

  3. The Townsville Hospital, Angus Smith Drive, Douglas, QLD, 4814, Australia

    Jodie Marsh, Chris Mitchell & Andrew Birchley

  4. Faculty of Medicine, The University of Queensland, 20 Weightman Street, Herston, QLD, 4006, Australia

    Glen A. Kennedy

Authors
  1. Midori Nakagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elise Button
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amy Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jodie Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chris Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Andrew Birchley
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Glen A. Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Midori Nakagaki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakagaki, M., Button, E., Keating, A. et al. Hyperhydration is not necessary for high-dose melphalan in stem cell transplantation. Bone Marrow Transplant 55, 827–829 (2020). https://doi.org/10.1038/s41409-019-0586-1

Download citation

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0586-1

Search

Advanced search

Quick links